FSHD Radio Hot off the Press: Mel Hayes of Fulcrum with a REACH Trial Update
Episode 108, Sep 28, 2023, 10:00 AM
Earlier this month, Fulcrum Therapeutics confirmed the completion of patient enrollment in the Phase 3 REACH clinical trial for losmapimod, a potential groundbreaking therapy for FSHD. Mel Hayes, Chief Operating Officer of Fulcrum sat down with Tim to discuss what this exciting milestone means and fill us in on the latest from Project Mercury.
Catch a new Hot off the Press episode on the 4th Thursday of every month. Listen on your favorite podcast app or watch on YouTube or Facebook. Subscribe to make sure you never miss an episode!
Catch a new Hot off the Press episode on the 4th Thursday of every month. Listen on your favorite podcast app or watch on YouTube or Facebook. Subscribe to make sure you never miss an episode!